| Metric | Value (₹ Cr) | Q4 FY25 | Q1 FY25 |
|---|---|---|---|
| Revenue | 406.30 | 24.2% | 0.0% |
| Total Income | 415.00 | 23.0% | 0.0% |
| Expenditure | 320.90 | 14.2% | 0.0% |
| PBT | 94.10 | 43.1% | 0.0% |
| Net Profit | 69.50 | 41.8% | 0.0% |
| OPM | 23.36% | 8.72pp | 0.20pp |
| NPM | 16.75% | 5.41pp | 0.36pp |
| EPS | 30.18 | 41.8% | 899.3% |
Sanofi India Ltd Reports -2% Net Sales YTD Growth and +6% Profit from Operations for Q2 2025
02 Aug 2025 · 2 Aug 2025, 12:02 pm
Summary
Sanofi India Ltd has reported a 9% decline in net sales on a comparable basis of continuing business for the quarter ended June 30, 2025. However, the company achieved a 6% increase in operating profit for the year-to-date period ended June 2025. The decline in sales was due to non-recurring CHC product sales from 2024 and the planned discontinuation of the Zentiva portfolio. The company's insulin portfolio, led by Toujeo® and Soliqua®, demonstrated robust growth. Sanofi India is committed to enhancing operational efficiency and broadening access to both established products and innovative therapies across India.
Key Highlights
- 1
9% decline in net sales on a comparable basis of continuing business
- 2
6% increase in operating profit for the year-to-date period ended June 2025
- 3
Successful launch of Soliqua® in the domestic market
- 4
High single-digit growth of Toujeo®
- 5
Strategic partnerships in Cardiovascular (CV) and Central Nervous System (CNS) segments
- 6
Sanofi India's insulin portfolio demonstrating robust growth
- 7
Commitment to enhancing operational efficiency and broadening access to both established products and innovative therapies across India
Management Comments
Rachid Ayari
During this transformative year for our company, our insulin portfolio has demonstrated robust growth, led by Toujeo® and the successful introduction of Soliqua® - our premium diabetes solution for the premix segment. Our strategic partnerships have effectively expanded our reach to healthcare professionals in both CV (Cardiovascular) and CNS (Central Nervous System) therapeutic areas, meeting our planned objectives. Moving forward, we remain committed to enhancing operational efficiency while broadening access to both our established products and innovative therapies across India.
Informational and educational content only. Not investment advice.